Institute of Pharmaceutical Technology and Regulatory Affairs, Institute of Pharmacy, University of Szeged, Eötvös u. 6, H-6720 Szeged, Hungary; Institute of Pharmaceutical Technology and Regulatory Affairs, Interdisciplinary Centre of Excellence, University of Szeged, Eötvös u. 6, H-6720 Szeged, Hungary.
Department of Pharmaceutical Technology, Institute of Pharmacy, Leopold-Franzens-University Innsbruck, Innrain 80/82, 6020 Innsbruck, Austria; Faculty of Pharmacy, University of Medicine and Pharmacy, Hue University, Thua Thien Hue, Viet Nam.
Eur J Pharm Biopharm. 2020 Jul;152:10-17. doi: 10.1016/j.ejpb.2020.04.025. Epub 2020 May 3.
The lipophilic character of peptides can be tremendously improved by hydrophobic ion pairing (HIP) with counterions to be efficiently incorporated into lipid-based nanocarriers (NCs). Herein, HIPs of exenatide with the cationic surfactant tetraheptylammonium bromide (THA) and the anionic surfactant sodium docusate (DOC) were formed to increase its lipophilicity. These HIPs were incorporated into lipid based NCs comprising 41% Capmul MCM, 15% Captex 355, 40% Cremophor RH and 4% propylene glycol. Exenatide-THA NCs showed a log D of 2.29 and 1.92, whereas the log D of exenatide-DOC was 1.2 and -0.9 in simulated intestinal fluid and Hanks' balanced salts buffer (HBSS), respectively. No significant hemolytic activity was induced at a concentration of 0.25% (m/v) of both blank and loaded NCs. Exenatide-THA NCs and exenatide-DOC NCs showed a 10-fold and 3-fold enhancement in intestinal apparent membrane permeability compared to free exenatide, respectively. Furthermore, orally administered exenatide-THA and exenatide-DOC NCs in healthy rats resulted in a relative bioavailability of 27.96 ± 5.24% and 16.29 ± 6.63%, respectively, confirming the comparatively higher potential of the cationic surfactant over the anionic surfactant. Findings of this work highlight the potential of the type of counterion used for HIP as key to successful design of lipid-based NCs for oral exenatide delivery.
通过与反离子形成疏水离子对(HIP),可以极大地提高肽的亲脂性,使其有效地整合到基于脂质的纳米载体(NCs)中。在此,通过与阳离子表面活性剂四庚基溴化铵(THA)和阴离子表面活性剂十二烷基硫酸钠(DOC)形成 HIP,以增加其亲脂性。将这些 HIP 整合到包含 41%Capmul MCM、15%Captex 355、40%Cremophor RH 和 4%丙二醇的基于脂质的 NCs 中。Exenatide-THA NCs 的 log D 分别为 2.29 和 1.92,而 Exenatide-DOC 的 log D 分别为在模拟肠液和 Hank's 平衡盐缓冲液(HBSS)中为 1.2 和-0.9。在 0.25%(m/v)的浓度下,空白和负载 NCs 均未引起明显的溶血活性。与游离 Exenatide 相比,Exenatide-THA NCs 和 Exenatide-DOC NCs 分别使肠黏膜表观渗透率提高了 10 倍和 3 倍。此外,在健康大鼠中口服给予 Exenatide-THA 和 Exenatide-DOC NCs 后,相对生物利用度分别为 27.96±5.24%和 16.29±6.63%,证实了阳离子表面活性剂相对于阴离子表面活性剂具有更高的潜力。这项工作的结果强调了用于 HIP 的反离子类型作为成功设计用于口服 Exenatide 传递的基于脂质的 NCs 的关键的潜力。